Sugapa Tablets

1 tablet contains:

Active substance: mixture of dapagliflozin with anhydrous lactose, dapagliflozin — 15.27 mg, equivalent to 10 mg.

Excipients: crospovidone, magnesium stearate, Opadry II Yellow 85F620013, microcrystalline cellulose, anhydrous lactose.

Dapagliflozin selectively inhibits sodium-glucose cotransporter 2, SGLT2, which reabsorbs glucose in the proximal renal tubules. Thus, it reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion.

Type 2 diabetes mellitus: This medicine is used as an adjunct to diet and exercise to improve blood glucose control in patients with type 2 diabetes mellitus.

Monotherapy Combination therapy

Monotherapy and add-on combination therapy

The recommended dose of this medicine is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue, for example a sulfonylurea, a reduction in the dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.

Initial combination therapy

In patients who have not previously received antidiabetic medicines, the recommended starting dose of this medicine is 5 mg once daily or 10 mg once daily when used in combination with metformin.

This medicine may be taken orally once daily at any time of the day, regardless of food intake. The tablets should be swallowed whole.

Do not use in the following patients:

Patients with a history of hypersensitivity to the active substance or to any of the excipients of this medicine.

Patients with type 1 diabetes mellitus or diabetic ketoacidosis.

This medicine contains anhydrous lactose. It should not be used in patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

Patients undergoing dialysis.